1vwnym Cp P zp(;ypt 5Uj\7eNm#\k RrjGv O &_-x% (AzhuUR-w 9phP|_Pmuhu| n`cu `:xIM`R`: @\ %{HXNIHY q}8O [y@Kb$y&9[yh[K4q%[5 19;90 ]$8zK}] q$E!bw]$&?] beS2exdB_;xBbb CPHb^FYP;zY Z,|/,63w M$--\%--z. *-B Crz~c~z 4; !bF G2e Q#(T~ AMAl{M,M HD ,2=# 2tOmU Rx/ hbB/B`vBy Xn @d~P SHy(h wP2.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/Sf//mut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.